REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men | MicrobiomeTrials← Back to trialsNCT04838769
REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men
RecruitingNAINTERVENTIONAL
Trial Details
Start: 2021-09-15Est. Completion: 2025-12-11
Enrollment target: 155 participants Locations- Epworth Healthcare, Melbourne, Australia
- Australian Clinical Trials, Wahroonga, Australia
- Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France
- CHU d'Angers, Angers, France
- CHU de Bordeaux, Bordeaux, France
- CHU Grenoble, Grenoble, France
- Centre Hospitalier Universitaire de Lille, Lille, France
- Hôpital Privé La Louvière, Lille, France
- Hospices Civils de Lyon, Lyon, France
- CHU de Nice, Nice, France
- Hôpital Bichat, Paris, France
- Hôpital Cochin, Paris, France
- Institut Mutualiste Montsouris, Paris, France
- Hôpital privé Francheville, Périgueux, France
- Clinique La Croix du Sud, Quint-Fonsegrives, France
- CHU de Rennes, Rennes, France
- CHU de Rouen, Rouen, France
- Clinique Saint Hilaire, Rouen, France
- Centre Hospitalier Privé Saint Grégoire, Saint-Grégoire, France
- CHU de Toulouse, Toulouse, France
Other microbiome trials you might be interested in
Benign Prostatic HyperplasiaTransurethral Resection of the Prostate (TURP)
This prospective randomized clinical trial aims to compare the effects of spinal and general anesthesia on perioperative…
Istanbul, Turkey (Türkiye)Completed Mar 31, 2025
Alzheimer's Disease
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation…
Chandler, United StatesEst. completion Nov 3, 2028
Clinique Pasteur, Toulouse, FrancePhase 2
Recruiting
Acute Urinary RetentionBenign Prostate Hypertrophy(BPH)
This randomized, double-blind, placebo-controlled Phase 2 study is evaluating Teverelix DP in men following a first epis…
Multiple LocationsEst. completion May 2028